Malgorzata Misiewicz
Lodz, LD 92215, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Journal: International journal of molecular sciences
Published: March 11, 2024
High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation.
Journal: Infection & chemotherapy
Published: February 10, 2024
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study.
Journal: Leukemia & lymphoma
Published: November 10, 2023
A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM/BEAM conditioning regimen and autologous stem cell transplantation.
Journal: Transplant infectious disease : an official journal of the Transplantation Society
Published: October 22, 2023
MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation.
Journal: Biomarker research
Published: October 13, 2023
High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
Journal: Frontiers in oncology
Published: June 30, 2023
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Journal: International journal of molecular sciences
Published: December 05, 2022
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.
Journal: Journal of clinical medicine
Published: November 25, 2021
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Journal: Journal of clinical medicine
Published: August 12, 2021
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
Journal: Cancers
Published: January 23, 2021
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Journal: Cancers
Published: July 22, 2020
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.
Journal: Mediators of inflammation
Published: January 17, 2020
Last Updated: 09/26/2026